PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1532825
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1532825
Cell and Gene Therapy Manufacturing Services Market size was valued at USD 5,977 Million in 2023, expanding at a CAGR of 17.2% from 2024 to 2032.
The Cell and Gene Therapy Manufacturing Services Market encompasses specialized services for the production of cell and gene therapies, which are revolutionary treatments targeting genetic disorders and various diseases. The rising prevalence of genetic disorders and cancer, coupled with advancements in personalized medicine, is fueling the market's expansion. However, challenges such as high production costs and complex regulatory requirements act as significant restraints. Opportunities are emerging in the form of increased investments in research and development, with global funding for cell and gene therapies having surged by approximately 30% in the past year. Additionally, partnerships between biotech firms and contract manufacturing organizations (CMOs) are on the rise, aiming to streamline production processes and enhance scalability.
Cell and Gene Therapy Manufacturing Services Market- Market Dynamics
Growing Prevalence of Genetic Disorders and Cancer Fuels Need for Cell and Gene Therapy Manufacturing Services
The increasing prevalence of genetic disorders and cancer is significantly driving the demand for Cell and Gene Therapy Manufacturing Services. For instance, the National Cancer Institute reports that nearly 1.9 million new cancer cases were expected in the U.S. alone in 2024, underscoring the urgent need for advanced therapeutic solutions. Similarly, the World Health Organization notes that genetic disorders affect about 1 in 20 people globally, amplifying the need for specialized therapies. Recent investments in this field have been notable, with the National Institutes of Health allocating over $1 billion in grants for gene therapy research in the past year. Additionally, leading companies like Novartis and Bluebird Bio have expanded their manufacturing capabilities to meet the rising demand for these cutting-edge treatments, reflecting a growing focus on improving patient outcomes through innovative therapies.
Cell and Gene Therapy Manufacturing Services Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 17.2% over the forecast period (2024-2032)
Based on Therapy Type segmentation, Gene Therapy was predicted to show maximum market share in the year 2023
Based on Cell Type segmentation, Autologous Cells was the leading type in 2023
Based on Service Type segmentation, Contract Development and Manufacturing Organization (CDMO) was the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Cell and Gene Therapy Manufacturing Services Market is segmented based on Therapy Type, Cell Type, Service Type, End-User, and Region.
The market is divided into two categories based on Therapy Type: Cell Therapy and Gene Therapy. Cell Therapy focuses on the production and manipulation of cells for therapeutic use, while Gene Therapy involves the development of treatments that alter genetic material to address diseases.
The market is divided into two categories based on Cell Type: Autologous Cells and Allogeneic Cells. Autologous Cells are derived from the patient's own body, ensuring compatibility, while Allogeneic Cells are sourced from donors and offer broader application potential.
Cell and Gene Therapy Manufacturing Services Market- Geographical Insights
North America, particularly the United States, leads the market due to its advanced research infrastructure, substantial funding, and a robust network of specialized manufacturing facilities. In Europe, countries such as Germany and the United Kingdom are also significant players, benefiting from strong regulatory frameworks and increasing collaboration between biotech companies and research institutions. Meanwhile, the Asia-Pacific region is emerging rapidly, with countries like China and Japan investing heavily in biotech innovations and expanding their manufacturing capabilities. For example, China's recent $500 million investment in gene therapy infrastructure reflects its growing focus on becoming a major player in this sector.
Key players such as Lonza, Catalent, and WuXi AppTec dominate the market with extensive manufacturing capabilities and global reach, providing a range of services from cell processing to gene editing. These companies are bolstered by significant investments in cutting-edge technologies and strategic partnerships. For instance, Lonza's collaboration with Novartis to enhance manufacturing capacity for CAR-T cell therapies highlights the trend towards deepening industry alliances. Emerging biotech firms and contract manufacturing organizations (CMOs) also play a crucial role, offering specialized services and driving innovation. The competitive environment is characterized by continuous advancements in technology, regulatory adaptations, and an emphasis on scalable and efficient manufacturing solutions.
In May 2024, ProPharma, in collaboration with PBL, introduced the Cell Factory Box (CF Box), a fully automated and enclosed cell factory device designed for the production of cell and gene therapies (CGTs). The CF Box facilitates decentralized manufacturing of various CGTs within Class D (ISO8) or controlled, non-classified environments.
In May 2024, Bristol Myers Squibb signed a USD 380 million deal with Cellares to produce CAR T-cell therapies, highlighting the rising demand for outsourced cell and gene therapy manufacturing services. Cellares plans to expand its automated manufacturing units in the US, Europe, and Japan.
GLOBAL CELL AND GENE THERAPY MANUFACTURING SERVICES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Adaptimmune Therapeutics plc
Bluebird Bio, Inc.
Catalent, Inc.
Celyad Oncology SA
Charles River Laboratories International, Inc.
Gene Therapy Research Group
Kiadis Pharma N.V.
Lonza Group AG
MaxCyte, Inc.
Miltenyi Biotec GmbH
Orchard Therapeutics plc
Rocket Pharmaceuticals, Inc.
Sangamo Therapeutics, Inc.
Sarepta Therapeutics, Inc.
TCR2 Therapeutics Inc.
WuXi AppTec
Others